- Home
- NRXS vs ASBP Comparison
NRXS vs ASBP Comparison
Compare NRXS & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- ASBP
- Stock Information
- Founded
- NRXS 2011
- ASBP 2021
- Country
- NRXS United States
- ASBP United States
- Employees
- NRXS N/A
- ASBP N/A
- Industry
- NRXS
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- ASBP Health Care
- Exchange
- NRXS Nasdaq
- ASBP Nasdaq
- Market Cap
- NRXS 13.0M
- ASBP 11.9M
- IPO Year
- NRXS 2023
- ASBP N/A
- Fundamental
- Price
- NRXS $2.38
- ASBP $0.28
- Analyst Decision
- NRXS Strong Buy
- ASBP
- Analyst Count
- NRXS 1
- ASBP 0
- Target Price
- NRXS $7.00
- ASBP N/A
- AVG Volume (30 Days)
- NRXS 141.2K
- ASBP 4.0M
- Earning Date
- NRXS 08-08-2025
- ASBP 08-24-2025
- Dividend Yield
- NRXS N/A
- ASBP N/A
- EPS Growth
- NRXS N/A
- ASBP N/A
- EPS
- NRXS N/A
- ASBP N/A
- Revenue
- NRXS $2,934,945.00
- ASBP N/A
- Revenue This Year
- NRXS $138,883.78
- ASBP N/A
- Revenue Next Year
- NRXS $118.59
- ASBP N/A
- P/E Ratio
- NRXS N/A
- ASBP N/A
- Revenue Growth
- NRXS 27.52
- ASBP N/A
- 52 Week Low
- NRXS $1.33
- ASBP $0.22
- 52 Week High
- NRXS $6.20
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- NRXS 45.38
- ASBP N/A
- Support Level
- NRXS $2.33
- ASBP N/A
- Resistance Level
- NRXS $2.65
- ASBP N/A
- Average True Range (ATR)
- NRXS 0.15
- ASBP 0.00
- MACD
- NRXS -0.02
- ASBP 0.00
- Stochastic Oscillator
- NRXS 29.27
- ASBP 0.00
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.